We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 19 of 3261 for:    Louisville

Intraoperative Amiodarone to Prevent Atrial Fibrillation in Lung Transplant Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03221764
Recruitment Status : Recruiting
First Posted : July 19, 2017
Last Update Posted : November 17, 2017
Sponsor:
Information provided by (Responsible Party):

July 10, 2017
July 19, 2017
November 17, 2017
October 19, 2017
June 30, 2019   (Final data collection date for primary outcome measure)
Number of patients developing atrial fibrillation after lung transplant [ Time Frame: Patients will be monitored for up to one year following lung transplant ]
Patients will be continuously on monitored via telemetry for development of atrial arrhythmias during their post-operative hospital stay
Same as current
Complete list of historical versions of study NCT03221764 on ClinicalTrials.gov Archive Site
  • Length of hospital stay after transplant [ Time Frame: From transplant to discharge from hospital, up to 1 year ]
    Assessing length of stay in hospital after lung transplant - measured from time of transplant until initial discharge from hospital
  • 30 Day Survival [ Time Frame: 30 Day ]
    Survival
Same as current
Not Provided
Not Provided
 
Intraoperative Amiodarone to Prevent Atrial Fibrillation in Lung Transplant Patients
The Intra-Operative Application of Amiodarone Releasing Hydrogel to Prevent Postoperative Atrial Fibrillation in Patients Undergoing Lung Transplantation
This study will prospectively evaluate the use of an amiodarone releasing hydrogel applied to the pulmonary veins and atria at the time of lung transplantation. This study will include patients undergoing lung transplantation at Jewish Hospital, Louisville KY. The prospective group will be compared to historical controls from the same institution. Investigators will access medical records and database entries for those patients undergoing lung transplantation after January 1st 2005 in order to obtain matched controls for analysis. Informed consent will be obtained from the prospective cohort prior to patient enrollment. This pilot study will be used to obtain preliminary data in order to proceed with a larger randomized control trial.

Approximately 1900 transplants are performed in the US annually. Lung transplantation remains the gold standard treatment for patients with end stage lung disease. This includes patients with range of etiologies such as Idiopathic Pulmonary Fibrosis, COPD and Cystic Fibrosis. One of the more common post-operative complications in patients undergoing lung transplantation is the development of atrial fibrillation. Recent studies have demonstrated that approximately 1/3 of patients will develop atrial fibrillation during their post-operative course. While it is uncertain if the development of post-operative atrial fibrillation affects survival, it does significantly increase length of hospital stay. Importantly, a portion of the patients that develop atrial fibrillation post-operatively will require cardioversion prior to discharge.

Currently one of the main stays of treatment for post-operative atrial fibrillation is systemic (oral or intravenous) amiodarone, which is a class III antiarrhythmic agent. While this particular drug is effective, it does carry the risk of several known complications. Due to the drug's pharmacokinetics, amiodarone concentrates in organs with high lipid content such as the thyroid, liver and lung. Amiodarone has several known adverse effects on the lung ranging from acute respiratory distress syndrome to more chronic disease such as Interstitial pulmonary fibrosis. Amiodarone can have detrimental effects on the liver which in rare cases could lead to cirrhosis. Additionally, amiodarone can cause thyrotoxicosis as early as a few weeks after the initiation of amiodarone.

The adverse events listed above are related to the cumulative dose of amiodarone. Typically, when amiodarone is initiated, patients receive a loading dose of 600-800mg daily until the cumulative dose reaches 10 grams, after which patients will receive 200mg daily as a maintenance dose. Minimizing the cumulative dose of amiodarone by using a local application, could mitigate the potential adverse drug toxicities. In a previous study, the application of an amiodarone releasing hydrogel performed intraoperatively was shown to significantly decrease the rates of post-operative atrial fibrillation in patients undergoing coronary artery bypass. Currently for patients undergoing lung transplantation, there is not a safe and effective measure available to prevent post-operative atrial fibrillation.

The Investigators aim to study the intraoperative application of an amiodarone containing hydrogel for prevention of post-operative atrial fibrillation in lung transplant patients.

In patients undergoing lung transplantation, post-operative atrial fibrillation is common and leads to prolonged hospital course and increased healthcare expenditures. Amiodarone is a main stay of therapy for atrial fibrillation, however this drug does have potential serious complications when administered systemically. The local application of amiodarone, could potentially decrease the rates of atrial fibrillation, while avoiding the systemic complications. This has the potential to decrease length of stay and decrease additional procedures (ie. Cardioversion) in patients undergoing lung transplantation.

Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Atrial Fibrillation
  • Lung Transplant; Complications
  • Drug: Amiodarone with CoSeal
    CoSeal Surgical Sealant (Baxter Healthcare) consist of 2 formulations of synthetic polyethylene glycols, a dilute hydrogen chloride solution along with a sodium phosphate/sodium carbonate solution. These separate solutions are mixed at the time of application to form a hydrogel. Amiodarone hydrochloride powder (1mg/kg) will be mixed with CoSeal at the time of application to form an amiodarone containing hydrogel. The dosing of amiodarone is based on previous study using amiodarone hydrogel in post-operative coronary artery bypass patients [8]. This hydrogel will be delivered utilizing a CO2 driver along the pulmonary vein and arterial anastomoses, and to the surface right and left atria.
    Other Name: Amiodarone with CoSealadministered with CO2 driver
  • Device: CO2 driver
    The amiodarone hydrogel will be delivered utilizing a CO2 driver along the pulmonary vein and arterial anastomoses, and to the surface right and left atria.
Experimental: Amiodarone with CoSeal administered with CO2 driver
Lung Transplant Recipients who receive Intraoperative application of an Amiodarone containing hydrogel at the time of transplant.
Interventions:
  • Drug: Amiodarone with CoSeal
  • Device: CO2 driver
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
20
July 31, 2019
June 30, 2019   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject or legal representative has signed Informed Consent Form (ICF)
  • Undergoing lung transplant at the Jewish Hospital
  • Age ≥ 18 years
  • Subjects willing and able to comply with the follow up requirements of the study

Exclusion Criteria:

  • Patients with previous history of atrial fibrillation.
  • Patients with previously documented allergy or adverse reaction to amiodarone.
  • Patients with previous ablation for atrial fibrillation
  • Patients with an implantable pacemaker.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact: Victor H van Berkel, MD, PHD 5025887601 victor.vanberkel@ulp.org
United States
 
 
NCT03221764
16.1213
Not Provided
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Not Provided
Victor Van Berkel, University of Louisville
University of Louisville
Not Provided
Principal Investigator: Victor H van Berkel, MD, PHD University of Louisville
University of Louisville
November 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP